crushed prasugrel tablets in patients with stemi undergoing primary percutaneous coronary intervention the crush study外文参考.pdf

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY ,,2016
ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$
PUBLISHED BY ELSEVIER /
Crushed Prasugrel Tablets in Patients
With STEMI Undergoing Primary
Percutaneous Coronary Intervention
The CRUSH Study
Fabiana Rollini, MD, Francesco Franchi, MD, Jenny Hu, MD, Megha Kureti, MD, Niti Aggarwal, MD,
Ashwin Durairaj, MD, Yongwhi Park, MD, Michael Seawell, MD, Pedro Cox-Alomar, MD, Martin M. Zenni, MD,
Luis A. Guzman, MD, Siva Suryadevara, MD, Patrick Antoun, MD, Theodore A. Bass, MD,
Dominick J. Angiolillo, MD, PHD
ABSTRACT
BACKGROUND Platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with
ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI),
which may be attributed to impaired absorption affecting drug pharmacokinetics (PK) and pharmacodynamics (PD).
Crushing tablets has been suggested to lead to more favorable PK/PD profiles. To date, no studies have investigated the
PK/PD effects of crushing prasugrel.
OBJECTIVES This study sought to determine whether crushing prasugrel is associated with more favorable drug
bioavailability and platelet inhibitory effects compared with whole tablets in STEMI patients undergo